C

    Century Therapeutics Inc (IPSC)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $2.02
    -0.20 (-9.19%)

    Market Cap: $366.68M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    55%(12/22)
    Avg Surprise
    -30.24%

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.11
    Range$-0.12 - $-0.08
    4 analysts
    EPS RevisionsNo revisions (7d)No revisions (30d)
    EPS Estimate Drift
    90d ago$-0.12-12.1%
    60d ago$-0.12-12.1%
    30d ago$-0.12-12.1%
    7d ago$-0.12-12.1%
    Current$-0.11
    Revenue Consensus
    $0
    Range$0 - $0
    5 analysts
    Dec 31, 2026
    EPS Consensus$-0.05
    Range$-0.11 - $0.03
    3 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    5 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.05---
    Sep 26EST
    		-$-0.11---
    Jun 26
    		$-0.17$-0.11-54.55%Miss+55.3%
    Mar 26
    		$-0.11$-0.17+35.29%Beat-112.4%
    Dec 25
    		$-0.25$-0.30+15.97%Beat+41.9%
    Sep 25
    		$-0.32$-0.38+15.79%Beat+13.5%
    Jun 25
    		$-0.38$-0.37-2.70%Miss+0.0%
    Mar 25
    		$0.89$-0.31+387.10%Beat+297.8%
    Dec 24
    		$-0.43$-0.45+4.44%Beat+33.8%
    Sep 24
    		$-0.37$-0.45+17.78%Beat+32.7%
    Jun 24
    		$-0.38$-0.50+24.00%Beat+22.4%
    Mar 24
    		$-0.45$-0.45+0.00%Beat+15.1%
    Dec 23
    		$-0.65$-0.55-18.18%Miss+71.4%
    Sep 23
    		$-0.55$-0.49-12.24%Miss-3.8%
    Jun 23
    		$-0.49$-0.54+9.26%Beat+9.3%
    Mar 23
    		$-0.53$-0.52-1.92%Miss-10.4%
    Dec 22
    		$-2.27$-0.59-284.75%Miss-845.8%
    Sep 22
    		$-0.53$-0.60+11.67%Beat-10.4%
    Jun 22
    		$-0.54$-0.50-8.00%Miss+72.0%
    Mar 22
    		$-0.48$-0.54+11.11%Beat+79.9%
    Dec 21
    		$-0.24$-0.48+50.00%Beat+74.8%
    Sep 21
    		$-0.48$-0.42-14.29%Miss+6.6%
    Jun 21
    		$-1.93$-0.38-407.89%Miss-
    Mar 21
    		$-2.39$-0.44-443.18%Miss-
    Dec 20
    		$-0.95$0.00N/AMiss-
    Dec 19
    		$-0.51$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-2.38EV/EBITDA131.51x
    Price/FCF-4.72xFCF Yield-21.21%
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-49.60%ROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current Ratio8.28xQuick Ratio8.28x
    Trading Statistics
    Beta1.60Avg Volume504.21K
    52-Week High$3.0452-Week Low$0.43

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$2.08
    SMA 20$2.02
    SMA 50$2.16
    SMA 200$1.91
    EMA 10$2.09
    EMA 20$2.07
    EMA 50$2.12
    EMA 200$1.88

    MACD

    Line: -0.00Signal: -0.02Hist: 0.02

    ADX

    ADX: 17.3+DI: 22.1-DI: 20.4

    Aroon & PSAR

    Aroon Up100.0
    Aroon Down36.0
    PSAR$1.97

    Bollinger Bands

    Upper Band$2.21
    Lower Band$1.84
    %B Position1782%(Upper)
    Band Width0.50

    RSI (14-Day)

    Neutral
    46.9

    Momentum Oscillators

    Stoch %K70.4
    Stoch %D81.4
    Williams %R-62.5
    ROC (10d)5.5%
    Momentum0.10
    CCI (20d)62.1
    MFI (14d)56.2

    Volatility Measures

    ATR (14d)$0.12(5.9%)
    StdDev (20d)0.09
    Hist Vol62.4%(High)

    Volume Flow

    VWAP$2.09
    OBV59.4M
    AD Line-410.7K
    CMF (20d)-0.123

    Volume Metrics

    Avg Vol (20d)503.6K
    Vol Ratio1.3x
    VWMA (20d)$2.02

    Pivot Points

    R3$2.37
    R2$2.31
    R1$2.27
    Pivot Point$2.21
    S1$2.17
    S2$2.11
    S3$2.07

    Advanced Oscillators

    TSI-0.31
    Ultimate Osc47.1
    KST-39.59

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$109.16M$4.17M$791,000$771,000$855,000$268,000$148,000
    Cost of Revenue$0$0$3.55M$0$0$0$3.32M$0$0$0$22.30M$0
    Gross Profit$0$0$-3,550,000$0$0$109.16M$4.17M$791,000$771,000$855,000$268,000$148,000
    Operating Expenses$36.53M$23.68M$20.66M$36.12M$34.66M$34.99M$41.46M$35.58M$35.53M$32.16M$44.03M$35.77M
    R&D$19.59M$17.11M$19.70M$22.53M$26.86M$26.58M$29.38M$27.23M$27.22M$23.42M$23.30M$26.79M
    SG&A$5.79M$6.58M$955,000$6.83M$7.80M$8.41M$7.75M$8.35M$8.31M$8.74M$8.59M$8.99M
    Operating Income$-36,527,000$-23,684,000$-20,657,000$-36,124,000$-34,664,000$74.18M$-37,284,000$-34,789,000$-34,755,000$-31,309,000$-43,762,000$-35,626,000
    Interest Income$1.98M$2.02M$1.31M$1.60M$2.01M$2.42M$2.88M$3.31M$3.58M$3.24M$3.51M$3.49M
    Interest Expense$0$0$0$0$0$74.18M$0$0$0$0$0$0
    Income Before Tax$0$0$-19,245,000$-34,422,000$0$0$-34,296,000$-31,234,000$-31,185,000$-28,061,000$-40,267,000$-32,128,000
    Income Tax Expense$0$0$-68,000$0$0$0$1.77M$-8,000$22,000$1,000$-869,000$592,000
    Net Income$-34,550,000$-21,645,000$-19,177,000$-34,422,000$-32,541,000$76.56M$-36,071,000$-31,226,000$-31,207,000$-28,062,000$-39,398,000$-32,720,000
    EBITDA$-34,065,000$-20,871,000$-17,353,000$-33,405,000$-31,997,000$76.50M$-34,894,000$-32,562,000$-32,648,000$-29,187,000$-44,209,000$-32,264,000
    EBIT$-36,532,000$-23,664,000$-20,554,000$-36,027,000$-34,551,000$74.14M$-37,179,000$-34,539,000$-34,767,000$-31,298,000$-43,777,000$-35,614,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about IPSC

    News

    Century Therapeutics CEO Brent Pfeiffenberger Completes RSU Tax Withholding Share Transaction

    Brent Pfeiffenberger, President and CEO of Century Therapeutics, Inc. (NASDAQ:IPSC), had 31,172 common stock shares withheld by the company on August 14, 2026. This transaction was to cover tax withholding requirements related to the vesting of restricted stock units (RSUs). After this withholding, Pfeiffenberger directly owns 3,634,302 shares of Century Therapeutics common stock.

    Kalkine Media•8/19/26•
    Neutral

    Century Therapeutics (IPSC) CEO stock withheld for taxes

    Century Therapeutics (IPSC) CEO Brent Pfeiffenberger had 31,172 shares of common stock withheld by the company at $1.92 per share to cover tax withholding obligations associated with the vesting of restricted stock units. This transaction occurred on August 14, 2026, and is not a market sale. Following this withholding, Pfeiffenberger directly holds 3,634,302 shares of Century Therapeutics common stock.

    Stock Titan•8/18/26•
    Neutral

    Mizuho Securities Maintains Century Therapeutics(IPSC.US) With Buy Rating, Maintains Target Price $8

    Mizuho Securities has reiterated its Buy rating on Century Therapeutics (IPSC.US) and maintained its price target of $8. This indicates the firm's continued positive outlook on the company's stock performance and valuation.

    Moomoo•8/17/26•
    Bullish

    HC Wainwright Issues Pessimistic Forecast for IPSC Earnings

    HC Wainwright has lowered its Q3 2026 EPS forecast for Century Therapeutics (NASDAQ:IPSC) to a loss of $0.12 per share, down from a previous estimate of $0.11, while maintaining a "Buy" rating and a $5.00 price target. This revision follows Century Therapeutics reporting a Q2 loss of $0.17 per share, missing the consensus estimate of a $0.11 loss. The overall analyst consensus for IPSC is "Hold" with an average price target of $4.75, and institutional investors currently own approximately 50.2% of the company's stock.

    MarketBeat•8/17/26•
    Bearish

    TD Cowen Maintains Century Therapeutics(IPSC.US) With Buy Rating

    TD Cowen has reiterated its Buy rating on Century Therapeutics (IPSC.US). This indicates a continued positive outlook from the firm regarding the company's stock performance.

    Moomoo•8/13/26•
    Bullish

    Frequently Asked Questions About IPSC

    Does IPSC pay dividends?
    Century Therapeutics Inc (IPSC) does not currently pay a regular dividend.
    What is IPSC's market cap?
    Century Therapeutics Inc (IPSC) has a market capitalization of $366.68M with a current stock price of $2.02.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In